Navigation Links
Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R)
Date:4/2/2008

tes. Apidra(R) can be administered using an insulin pump, vial and syringe, the OptiClik(R) reusable insulin pen or intravenously under proper medical supervision in a clinical setting.

Apidra(R) is from the maker of Lantus(R) (insulin glargine [rDNA origin] injection), the number one prescribed insulin.*

IMPORTANT SAFETY INFORMATION FOR APIDRA(R)

Apidra(R) is for adults with type 1 or type 2 diabetes for the control of high blood sugar. Apidra(R) should normally be used with a longer-acting insulin. Do not use Apidra(R) during a low blood sugar reaction (hypoglycemia) or if you are allergic to insulin glulisine. Apidra(R) may also be infused subcutaneously by external insulin infusion pumps.

Apidra(R) differs from regular human insulin by its rapid onset and shorter duration of action. When used as a mealtime insulin, Apidra(R) should be given within 15 minutes before or within 20 minutes after starting a meal. Due to the short duration of action of Apidra(R), patients also require a longer-acting insulin or insulin infusion pump therapy. Any change of insulin should be made cautiously and only under medical supervision. Tell your doctor about all other medicines and supplements you are taking. Glucose monitoring is recommended for all patients with diabetes.

Possible side effects may include low blood sugar; injection site reactions, such as changes in fat tissue at the injection site; and allergic reactions, such as itching and rash. Less common, but potentially more serious or life-threatening, is generalized allergy to insulin, including anaphylactic reactions.

When used in a pump, do not mix Apidra(R) with any other insulin or liquid. If the pump or infusion set does not work right, you may not receive the right amount of insulin. Hypoglycemia, hyperglycemia, or ketosis can happen. Problems should be identified and corrected as quickly as possible.

Exercise or activity level may change the way your body uses ins
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
2. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
3. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
4. New York-Presbyterian/Weill Cornell is First New York Medical Center to Offer Tantalus Clinical Trial to Diabetes Patients
5. Reduced Lung Capacity Accelerates With Diabetes
6. Revised: Challenging the Norm May Lead to New Therapy for Type 2 Diabetes
7. Challenging the Norm May Lead to New Therapy for Type 2 Diabetes
8. Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
9. Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
10. UMDNJ-University Hospital in Newark to Tailor Diabetes Interventions for Low-Income and Minority Groups With Grant From the International Diabetes Federation
11. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Seven leading cancer physicians ... Oncology Research participated in studies ... 2009 San Antonio Breast Cancer ... the Henry B. Gonzalez Convention ... . Fifteen others presented their ...
(Date:12/14/2009)... BEACH, Fla., Dec. 14 Perry Baromedical, ... years, announces the launch of the Sigma Elite, ... technology of the Sigma Elite is available on ... ) and has a Patent Pending. ,, The ... Data Capture Via Computerized System for Each ...
(Date:12/14/2009)... Diagnostics, Inc. is pleased to announce that the ... patent number 7,599,057 titled "Method and Apparatus for ... the company. The patent covers the core technology ... issuance of this patent supports the underlying strategy ... and commercialization," said Dave Dingott, CEO and President ...
Breaking Medicine Technology:US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9Perry Baromedical Announces New Cutting Edge Technology With Patient Data Capture Capability 2Chinese Devil Dung Plant Could Be a Swine Flu Fighter 56608 1Some Parents Arent Giving Kids Pain Meds Post Surgery 56606 1Some Parents Arent Giving Kids Pain Meds Post Surgery 56606 2Some Parents Arent Giving Kids Pain Meds Post Surgery 56606 3Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 1Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 2Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 3Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 4Vespa Pink Campaign Supports Fight Against Breast Cancer 56604 5
(Date:12/14/2009)... AQUALIPO™ and NaturalFill™ revolutionary new liposuction and fat transfer treatments ... lips all in one minimally invasive treatment. , ... ... of AQUALIPO™ and NaturalFill™ can remove excess fat from the ... help people slim down, reduce facial wrinkling and enhance lips ...
(Date:12/14/2009)... ABBOTT PARK, Ill. and HOLLYWOOD, Fla., Dec. ... ABT ) announced today a definitive agreement ... LIMS ), a leading provider of laboratory ... in cash. ,, The acquisition strengthens ... market, providing advanced web-based applications to help ...
(Date:12/14/2009)... -- Heska Corporation (Nasdaq: HSKA ; ... of veterinary diagnostic and specialty products, today ... Company,s new DRI-CHEM® 7000 Veterinary Chemistry Analyzer ... ) ,, Customers receiving these analyzers have ... analyzer available to the veterinary in-clinic market. ...
(Date:12/14/2009)... Incorporated announced today that it has priced $400 ... a coupon of 6.9%. The notes will be ... 6.984%. The company anticipates using the proceeds from ... purposes. ,, Commenting on the pricing of the ... Officer Kriss Cloninger III commented: "This debt issuance ...
(Date:12/14/2009)... Dental Care (also known as Culver City Dentist ... care in Southern California. We provide treatments in general ... and periodontal treatments. Beverly Hills Dentist and ... with experienced and trusted dentists who provide these treatments ... is one of these trusted dentists. He is best ...
Breaking Medicine News(10 mins):Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 2Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4Health News:Heska Announces Installation of New Chemistry Analyzer 2Health News:Heska Announces Installation of New Chemistry Analyzer 3Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4Health News:United Dental Care, Gentle Care, Trusted Dentists 2Health News:United Dental Care, Gentle Care, Trusted Dentists 3
... Sydney and Boston believe they may have identified a gene ... very troublesome problem for people with diabetes. , The liver ... sugar (glucose) levels fall, the liver makes and releases more. ... doesn,t stop making sugar when it should, so blood sugar ...
... and Efficacy Study of Zolpidem Tartrate Sublingual ... As-Needed BasisEvaluation of Ondansetron Augmentation in the ... 21 Transcept Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of ...
... ST. PETERSBURG, Fla., May 21 Mosaica Partners ... the Health Information Technology for Economic and Clinical ... healthcare through health information exchange (HIE) in its ... the Economic Stimulus Package for Health Information Exchange." ...
... Patients with Challenging Anatomy Consistent with Superior Results ... New data presented today at EuroPCR from an ... XIENCE V(R) Everolimus Eluting Coronary Stent System demonstrated ... stent thrombosis and major adverse cardiac events (MACE) ...
... assisted reproductive technology should be made aware, researcher says ... to naturally conceived twins, those conceived through assisted reproductive ... admitted to neonatal intensive care, finds a new study. ... twins born in Western Australia between 1994 and 2000. ...
... (OTC Bulletin Board: MLSS), the recognized leader in advanced injection ... is scheduled to be held on Thursday, June 4, 2009 ... as of the close of business on April 10, 2009. ... of Brown, Rudnick, Berlack and Israels located at 7 Times ...
Other Medicine News:Health News:Regulating the sugar factory in diabetes 2Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 2Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 3Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 4Health News:Mosaica Partners Briefing Paper Identifies Leading Practices for States and Regions to Leverage ARRA Stimulus Funds for HIE 2Health News:Mosaica Partners Briefing Paper Identifies Leading Practices for States and Regions to Leverage ARRA Stimulus Funds for HIE 3Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 2Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 3Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 4Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 5Health News:Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study 6Health News:Fertility Treatment Twins More at Risk for Hospitalizations 2Health News:Milestone Scientific to Host 2009 Annual Meeting of Stockholders on Thursday, June 4, 2009 in New York City 2
Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm....
Polyester ribbon impregnated with conjugated Protein G - .25 OD per sq. cm....
Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Onyx Liquid Embolic System is a device utilized for the pre-surgical embolization of arteriovenous malformations (AVMs)....
Medicine Products: